Tenon Medical (NASDAQ:TNON – Get Free Report) and PolyPid (NASDAQ:PYPD – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.
Volatility and Risk
Tenon Medical has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.
Valuation and Earnings
This table compares Tenon Medical and PolyPid”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tenon Medical | $3.28 million | 2.70 | -$15.58 million | ($27.23) | -0.04 |
| PolyPid | N/A | N/A | -$29.02 million | ($4.30) | -0.67 |
Tenon Medical has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Tenon Medical, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Tenon Medical and PolyPid’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tenon Medical | -413.88% | -1,785.88% | -164.26% |
| PolyPid | N/A | -624.10% | -129.28% |
Insider & Institutional Ownership
22.7% of Tenon Medical shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 4.7% of Tenon Medical shares are held by insiders. Comparatively, 24.7% of PolyPid shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and target prices for Tenon Medical and PolyPid, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tenon Medical | 0 | 0 | 4 | 0 | 3.00 |
| PolyPid | 0 | 0 | 3 | 1 | 3.25 |
Tenon Medical presently has a consensus target price of $4.67, suggesting a potential upside of 298.86%. PolyPid has a consensus target price of $11.33, suggesting a potential upside of 290.80%. Given Tenon Medical’s higher probable upside, equities research analysts plainly believe Tenon Medical is more favorable than PolyPid.
Summary
PolyPid beats Tenon Medical on 9 of the 14 factors compared between the two stocks.
About Tenon Medical
Tenon Medical, Inc., a medical device company, engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico. The company offers CATAMARAN SI-Joint Fusion System to fuse sacroiliac joints (SI-Joints) to treat SI-Joint dysfunction that often causes severe lower back pain; and features fixation device that passes through the axial and sagittal planes of the ilium and sacrum, as well as transfixes the SI joints. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Receive News & Ratings for Tenon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
